hrcak mascot   Srce   HID

Acta Pharmaceutica, Vol. 60 No. 4, 2010.

Pregledni rad
https://doi.org/10.2478/v10007-010-0040-9

Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics

UNA GLAMOČLIJA   ORCID icon orcid.org/0000-0003-1206-6990 ; Hercegovinalijek d.o.o., 88000 Mostar, Bosnia and Herzegovina
ADLIJA JEVRIĆ-ČAUŠEVIĆ ; Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy,University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina

Puni tekst: engleski, pdf (127 KB) str. 387-406 preuzimanja: 1.100* citiraj
APA 6th Edition
GLAMOČLIJA, U. i JEVRIĆ-ČAUŠEVIĆ, A. (2010). Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics. Acta Pharmaceutica, 60 (4), 387-406. https://doi.org/10.2478/v10007-010-0040-9
MLA 8th Edition
GLAMOČLIJA, UNA i ADLIJA JEVRIĆ-ČAUŠEVIĆ. "Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics." Acta Pharmaceutica, vol. 60, br. 4, 2010, str. 387-406. https://doi.org/10.2478/v10007-010-0040-9. Citirano 27.05.2019.
Chicago 17th Edition
GLAMOČLIJA, UNA i ADLIJA JEVRIĆ-ČAUŠEVIĆ. "Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics." Acta Pharmaceutica 60, br. 4 (2010): 387-406. https://doi.org/10.2478/v10007-010-0040-9
Harvard
GLAMOČLIJA, U., i JEVRIĆ-ČAUŠEVIĆ, A. (2010). 'Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics', Acta Pharmaceutica, 60(4), str. 387-406. doi: https://doi.org/10.2478/v10007-010-0040-9
Vancouver
GLAMOČLIJA U, JEVRIĆ-ČAUŠEVIĆ A. Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics. Acta Pharm. [Internet]. 2010 [pristupljeno 27.05.2019.];60(4):387-406. doi: https://doi.org/10.2478/v10007-010-0040-9
IEEE
U. GLAMOČLIJA i A. JEVRIĆ-ČAUŠEVIĆ, "Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics", Acta Pharmaceutica, vol.60, br. 4, str. 387-406, 2010. [Online]. doi: https://doi.org/10.2478/v10007-010-0040-9

Sažetak
Due to new genetic insights, etiologic classification of diabetes is under constant scrutiny. Hundreds, or even thousands, of genes are linked with type 2 diabetes. Three common variants (Lys23 of KCNJ11, Pro12 of PPARG, and the T allele at rs7903146 of TCF7L2) have been shown to be predisposed to type 2 diabetes mellitus across many large studies. Individually, each of these polymorphisms is only moderately predisposed to type 2 diabetes. On the other hand, monogenic forms of diabetes such as MODY and neonatal diabetes are characterized by unique clinical features and the possibility of applying a tailored treatment.
Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of a number of medications. Mutations in genes important in drug absorption, distribution, metabolism and excretion (ADME) play a critical role in pharmacogenetics of diabetes.
There are currently five major classes of oral pharmacological agents available to treat type 2 diabetes: sulfonylureas, meglitinides, metformin (a biguanide), thiazolidinediones, and α-glucosidase inhibitors. Other classes are also mentioned in literature.
In this work, different types of genetic mutations (mutations of the gene for glucokinase, HNF 1, HNF1ß and Kir6.2 and SUR1 subunit of KATP channel, PPAR-γ, OCT1 and OCT2, cytochromes, direct drug-receptor (KCNJ11), as well as the factors that influence the development of the disease (TCF7L2) and variants of genes that lead to hepatosteatosis caused by thiazolidinediones) and their influence on the response to therapy with oral antidiabetics will be reviewed.

Ključne riječi
pharmacogenetics; oral antidiabetics

Hrčak ID: 60285

URI
https://hrcak.srce.hr/60285

[hrvatski]

Posjeta: 1.608 *